^
    4d
    Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer (clinicaltrials.gov)
    P1, N=50, Active, not recruiting, Spectrum Pharmaceuticals, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    docetaxel • cyclophosphamide • Rolvedon (eflapegrastim-xnst)
    3ms
    A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy (clinicaltrials.gov)
    P2, N=40, Recruiting, Spectrum Pharmaceuticals, Inc | Trial completion date: Oct 2025 --> Oct 2027 | Trial primary completion date: Jul 2025 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    docetaxel • doxorubicin hydrochloride • cyclophosphamide • Rolvedon (eflapegrastim-xnst)
    3ms
    Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer (clinicaltrials.gov)
    P1, N=50, Recruiting, Spectrum Pharmaceuticals, Inc | N=90 --> 50 | Trial completion date: Jun 2025 --> Jul 2024 | Trial primary completion date: Dec 2024 --> Jul 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    docetaxel • cyclophosphamide • Rolvedon (eflapegrastim-xnst)
    3ms
    NEUTHREE: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (clinicaltrials.gov)
    P4, N=100, Recruiting, Eunseong Medical Foundation Good GANG-AN HOSPITAL | Not yet recruiting --> Recruiting | Trial completion date: Jan 2025 --> Jul 2025 | Initiation date: Aug 2023 --> Nov 2023 | Trial primary completion date: Jul 2024 --> Jan 2025
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Neulasta (pegfilgrastim) • Rolvedon (eflapegrastim-xnst)
    10ms
    Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer. (PubMed, Cancers (Basel))
    For patients with breast cancer, lipegfilgrastim 6 mg and eflapegrastim 13.2 mg might be the most effective regimen among LA-G-CSFs. Higher doses of LA-G-CSF may enhance efficacy without causing additional SAEs.
    Retrospective data • Review • Journal
    |
    Lonquex (lipegfilgrastim biosimilar) • Rolvedon (eflapegrastim-xnst)
    10ms
    NEUTHREE: Reducing Neutropenia Incidence With Pegfilgrastim Administration on Day 3 After Chemotherapy (clinicaltrials.gov)
    P4, N=100, Not yet recruiting, Eunseong Medical Foundation Good GANG-AN HOSPITAL
    New P4 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    Neulasta (pegfilgrastim) • Rolvedon (eflapegrastim-xnst)